SCHEMBL9901302

SCHEMBL9901302

CC1(C)COc2cccc(Oc3ccc([N+](=O)[O-])cc3)c21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 3/20 0.44
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
POLB P06746 2/20 0.40
KDM4E B2RXH2 2/20 0.39
HTT P42858 1/20 0.39
MAPT P10636 4/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MLNR O43193 1/20 0.38
MMP1 P03956 1/20 0.38
MPO P05164 1/20 0.38
CYP1A2 P05177 1/20 0.38
GLA P06280 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22712642 0.83 MAPT (0.38) HSPB1ALDH1A1MEN1KMT2APOLB
SCHEMBL30193740 0.82 HSPB1 (0.49) HSPB1ALDH1A1MEN1KMT2APOLB
SCHEMBL9905722 0.82 HSPB1 (0.49) HSPB1ALDH1A1MEN1KMT2APOLB
SCHEMBL9901409 0.81 MAPT (0.39) HSPB1ALDH1A1MEN1KMT2AMAPT
SCHEMBL9900837 0.81 NCOA1 (0.40) ALDH1A1MEN1KMT2APOLBHTT
SCHEMBL7632959 0.73 HSPB1 (0.66) HSPB1ALDH1A1MEN1KMT2AKDM4E
SCHEMBL19011643 0.73
SCHEMBL30964651 0.73 PIN1 (0.40) ALDH1A1MEN1KMT2AHTTMAPT
SCHEMBL1764615 0.72 HTR1A (0.40) ALDH1A1PTGS1
SCHEMBL10920087 0.71 HSPB1 (0.44) HSPB1ALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 US disclosed
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2020-11-19 US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 US disclosed
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUCTICS LIMITED (GB) 2019-04-23 US disclosed
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUCTICS LIMITED (GB) 2019-04-23 US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 US disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 EP disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 EP disclosed
EP-2649066-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2013-10-16 EP disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 HSPB1 1810/4885ALDH1A1 1966/4885MEN1 1596/4885
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 HSPB1 1810/4885ALDH1A1 1966/4885MEN1 1596/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 HSPB1 1810/4885ALDH1A1 1966/4885MEN1 1596/4885
US-20200360379-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 HSPB1 1810/4885ALDH1A1 1966/4885MEN1 1596/4885
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNA3, KCND3, KCNN3 HSPB1 1929/4885ALDH1A1 1789/4885MEN1 1367/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 HSPB1 1929/4885ALDH1A1 1789/4885MEN1 1367/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 HSPB1 1810/4885ALDH1A1 1966/4885MEN1 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.